5-methyl-1-phenylpyrazole-4-sulfonic acid | 1353503-21-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-methyl-1-phenylpyrazole-4-sulfonic acid
• 英文别名: 5-Methyl-1-phenyl-1H-pyrazole-4-sulfonic acid
• CAS: 1353503-21-5
• 化学式: C₁₀H₁₀N₂O₃S
• 分子量: 238.267
• InChiKey: UJMHYBRICVZOGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  80.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-methyl-1-phenylpyrazole-4-sulfonic acid 在 硫酸 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 为溶剂， 反应 7.0h， 生成 2,5-dimethyl-1-phenylpyrazol-2-ium-4-sulfonate
  参考文献：
  名称：

  Dreger, Andrij; Muenster, Niels; Nieto-Ortega, Belen, ARKIVOC, 2012, vol. 2012, # 3, p. 20 - 37

  摘要：

  DOI：
• 作为产物：
  描述：

  5-甲基-1-苯基-1H-吡唑 在 氯磺酸 作用下， 以 氯仿 为溶剂， 反应 2.0h， 以99%的产率得到5-methyl-1-phenylpyrazole-4-sulfonic acid
  参考文献：
  名称：

  Dreger, Andrij; Muenster, Niels; Nieto-Ortega, Belen, ARKIVOC, 2012, vol. 2012, # 3, p. 20 - 37

  摘要：

  DOI：

文献信息

• Substituted Azetidine compounds, their preparation and use as medicaments
  申请人：Cuberes Altisen Rosa

  公开号：US20050187208A1

  公开（公告）日：2005-08-25

  The present invention relates to substituted Azetidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

  本发明涉及通式（I）的取代氮杂环丙烷化合物，其制备方法，包含这些化合物的药物以及它们用于制备治疗人类和动物的药物的用途。
• Phenylglycine derivatives useful as serine protease inhibitors
  申请人：——

  公开号：US20040204412A1

  公开（公告）日：2004-10-14

  Compounds having the formula (I), 1 or a stereoisomer or pharmaceutically-acceptable salt, or hydrate thereof, are useful as factor VIIa inhibitors, wherein X is —NR 6 S(O) p R 16 ; W is hydrogen or —(CR 7 R 8 ) q W 1 ; W 1 is hydrogen or a bond with R 6 ; Z is a 5 -membered heteroaryl group, a five to six membered heterocyclo or cycloalkyl group, a 9 to 10 membered bicyclic aryl or heteroaryl, or a six membered aryl or heteroaryl, and R 1 , R 2 , R 3 , R 6 , R 7 , and R 16 are as defined in the specification.

  具有公式（I）的化合物，或其立体异构体或药学上可接受的盐或水合物，可用作因子VIIa抑制剂，其中X为—NR6S(O)pR16；W为氢或—(CR7R8)qW1；W1为氢或与R6相连的键；Z为5-成员杂芳基团，五至六成员杂环或环烷基团，9-至10-成员双环芳基或杂芳基，或六成员芳基或杂芳基，而R1、R2、R3、R6、R7和R16如说明书所定义。
• Substituted azetidine compounds, their preparation and use as medicaments
  申请人：Cuberes Altisen Rosa

  公开号：US20070066587A1

  公开（公告）日：2007-03-22

  The present invention relates to substituted Azetidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

  本发明涉及一般式（I）的取代的氮杂四元环化合物，其制备方法，包含这些化合物的药物以及它们用于制备用于治疗人类和动物的药物的用途。
• HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF
  申请人：Sumida Takumi

  公开号：US20100261720A1

  公开（公告）日：2010-10-14

  The present invention provides a heterocyclic compound represented by General Formula (1): wherein R 1 is a group R 5 —Z 1 —, etc., Z 1 is a lower alkylene group, etc., and R 5 is a group represented by General Formula; wherein R 13 is a hydrogen atom, etc., m is an integer from 1 to 5; R 2 is a hydrogen atom: Y is CH or N: A 1 is a heterocyclic ring selected from the group consisting of indolediyl groups, wherein the heterocyclic ring may have at least one substituent: T is a group —CO—, etc.: R 3 is a hydrogen atom, etc.: R 4 is a lower alkyl group optionally substituted by one or more hydroxy groups, etc.: R 3 and R 4 , together with the nitrogen atom to which they bind, may bind to each other and form a 5- to 10-membered saturated heterocyclic ring, wherein the heterocyclic ring may have at least one substituent. The heterocyclic compound of the present invention has excellent effects of suppressing the production of collagen and/or treating tumors.

  本发明提供一种由通式(1)表示的杂环化合物：其中R1为R5-Z1-等基团，Z1为低碳烷基等，而R5则为通式所表示的基团；其中R13为氢原子等，m为1到5的整数；R2为氢原子；Y为CH或N；A1为选自吲哚二基基团等的杂环环；其中该杂环环可以具有至少一个取代基；T为-CO-等基团；R3为氢原子等；R4为低碳基基团，可以选择性地被一个或多个羟基取代等；R3和R4与它们所结合的氮原子一起可以结合成一个5-到10-成员的饱和杂环环，其中该杂环环可以具有至少一个取代基。本发明的杂环化合物具有抑制胶原蛋白产生和/或治疗肿瘤的优异效果。
• PHENYLGLYCINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1594505A2

  公开（公告）日：2005-11-16